Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 3 (3), 218-21

Fatal Neutropenic Enterocolitis During Pegylated Interferon and Ribavirin Combination Therapy for Chronic Hepatitis C Virus Infection


Fatal Neutropenic Enterocolitis During Pegylated Interferon and Ribavirin Combination Therapy for Chronic Hepatitis C Virus Infection

Ji Hun Kim et al. Gut Liver.


It is known that neutropenia caused by combination pegylated interferon plus ribavirin therapy for hepatitis C virus (HCV) infection is well tolerated and carries a negligible risk of infection. Neutropenic enterocolitis is encountered most frequently in patients with hemato-oncologic diseases who are undergoing intensive chemotherapy. However, little information exists regarding this life-threatening event in the setting of HCV therapy. We present here an unusual case of fatal neutropenic enterocolitis in a cirrhotic patient receiving combination therapy for HCV infection. This is the first report of a death from neutropenic enterocolitis associated with treatment for chronic HCV infection. The present case suggests that caution should be exercised when continuing HCV therapy in neutropenic patients with advanced fibrosis, and the decision to maintain such therapy should be balanced against the potential for serious adverse events.

Keywords: Hepatitis C; Interferons; Neutropenic enterocolitis.


Fig. 1
Fig. 1
Ultrasonography of the liver showing (A) a coarse echotexture of the parenchyma, an irregular nodular surface, and (B) splenomegaly (approximately 13 cm).
Fig. 2
Fig. 2
Serial changes in the white blood cell count (WBC) and absolute neutrophil counts (ANCs) after pegylated interferon and ribavirin combination therapy.
Fig. 3
Fig. 3
CT scan on admission of a patient who presented with symptoms of neutropenic enterocolitis. (A) Edematous wall thickening of the ascending colon with pericolic strands. (B) Cirrhotic liver with minimal ascites in the perihepatic space, and splenomegaly.

Similar articles

See all similar articles

Cited by 2 PubMed Central articles


    1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52. - PubMed
    1. Deutsch M, Hadziyannis SJ. Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat. 2008;15:2–11. - PubMed
    1. Baek YH, Lee SW, Yoo HS, et al. Thymosin alpha-1 in combination with pegylated Interferon and ribavirin in chronic hepatitis C patients who have failed to prior pegylated interferon and ribavirin treatment. Gut Liver. 2007;1:87–89. - PMC - PubMed
    1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. - PubMed
    1. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2002;36:1273–1279. - PubMed

LinkOut - more resources